BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.59
-0.24 (-3.07%)
At close: Dec 5, 2025, 4:00 PM EST
7.62
+0.03 (0.40%)
After-hours: Dec 5, 2025, 7:10 PM EST
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for BioCryst Pharmaceuticals stock have an average target of 19, with a low estimate of 9.00 and a high estimate of 30. The average target predicts an increase of 150.33% from the current stock price of 7.59.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $27 → $25 | Buy | Maintains | $27 → $25 | +229.38% | Nov 5, 2025 |
| Barclays | Barclays | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +18.58% | Nov 4, 2025 |
| Needham | Needham | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | +137.15% | Nov 4, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +295.26% | Oct 15, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $24 → $26 | Buy | Maintains | $24 → $26 | +242.56% | Oct 15, 2025 |
Financial Forecast
Revenue This Year
631.89M
from 450.71M
Increased by 40.20%
Revenue Next Year
680.62M
from 631.89M
Increased by 7.71%
EPS This Year
0.17
from -0.43
EPS Next Year
0.29
from 0.17
Increased by 74.77%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 655.5M | 726.0M | ||||
| Avg | 631.9M | 680.6M | ||||
| Low | 600.8M | 613.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 45.4% | 14.9% | ||||
| Avg | 40.2% | 7.7% | ||||
| Low | 33.3% | -2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.49 | 0.53 | ||||
| Avg | 0.17 | 0.29 | ||||
| Low | 0.08 | 0.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 212.9% | ||||
| Avg | - | 74.8% | ||||
| Low | - | -94.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.